Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial ; volume:7 ; number:1 ; day:11 ; month:11 ; year:2012 ; pages:1-9 ; date:12.2012
Orphanet journal of rare diseases ; 7, Heft 1 (11.11.2012), 1-9, 12.2012
- Urheber
-
Cabrera-López, Cristina
- Beteiligte Personen und Organisationen
-
Marti, Teresa
Catalá, Violeta
Torres, Ferran
Mateu, Silvia
Ballarín, Jose
Torra, Roser
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-7-87
- URN
-
urn:nbn:de:1111-2016050120868
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.11.2025, 10:21 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cabrera-López, Cristina
- Marti, Teresa
- Catalá, Violeta
- Torres, Ferran
- Mateu, Silvia
- Ballarín, Jose
- Torra, Roser
- SpringerLink (Online service)
Ähnliche Objekte (12)
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Focal gigantism in tuberous sclerosis
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Bilateral renal angiomyolipomas in tuberous sclerosis
Tuberous Sclerosis Complex with Lung Involvement
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Radiosensitivity in individuals with tuberous sclerosis complex
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Focal gigantism in tuberous sclerosis
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Bilateral renal angiomyolipomas in tuberous sclerosis
Tuberous Sclerosis Complex with Lung Involvement
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Radiosensitivity in individuals with tuberous sclerosis complex
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Focal gigantism in tuberous sclerosis
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Bilateral renal angiomyolipomas in tuberous sclerosis
Tuberous Sclerosis Complex with Lung Involvement
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations